Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study.

Sci Rep · 2025 · PMC11718262 · PMID 39789026

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While our findings indicate a significant decreasing trend in MAP and DBP over 7 years of empagliflozin quadruple therapy, the results did not reach statistical significance for SBP.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.